Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05435495 · ClinicalTrials.gov registry record
Mechanisms of Resistance to PSMA Radioligand Therapy
A clinical trial of Prostate Cancer, sponsored by University of California, San Francisco.
- Recruiting
- Registry status
- 125
- Enrollment target
- 3
- Study locations
NCT05435495 is a study of Prostate Cancer that is actively recruiting participants, run by University of California, San Francisco. The registered enrollment target is 125 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (79% lower). The trial reports 3 study locations across 2 states.
The verdict
NCT05435495, a study of Prostate Cancer, is actively recruiting participants, sponsored by University of California, San Francisco.
- RECRUITING
- Registry status
- 125 participants
- Enrollment target
- 3
- Study locations
Study Summary
This is a multicenter, correlative study to existing Lutetium based prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) trials and uses.
Conditions Studied
Interventions
- PROCEDURE Blood Draw
- PROCEDURE Single-photon emission computed tomography
- PROCEDURE Tumor Biopsy
Study Locations (3)
California
- University of California, Los Angeles - Los Angeles
- University of California, San Francisco - San Francisco
New York
- Memorial Sloan Kettering - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 125 participants |
| Start Date | 2021-10-21 |
| Est. Completion | 2026-12-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05435495
The ClinicalTrials.gov registry entry for NCT05435495 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 125 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (79% lower). The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 3 interventions - of which Blood Draw is the first listed.
NCT05435495 reports 3 study locations spanning 2 distinct geographic areas - top geographies include California, New York.
Frequently Asked Questions
What is clinical trial NCT05435495 about?
NCT05435495 is a clinical study titled "Mechanisms of Resistance to PSMA Radioligand Therapy". This is a multicenter, correlative study to existing Lutetium based prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) trials and uses.
What is the current status of trial NCT05435495?
This trial is currently recruiting. The enrollment target is 125 participants. The study started on 2021-10-21. Estimated completion is 2026-12-31.
What conditions does trial NCT05435495 study?
This clinical trial studies the following conditions: Prostate Cancer.
What interventions are being tested in trial NCT05435495?
The interventions under investigation include: Blood Draw (PROCEDURE), Single-photon emission computed tomography (PROCEDURE), Tumor Biopsy (PROCEDURE).
Who is sponsoring clinical trial NCT05435495?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05435495 being conducted?
This trial has 3 study locations across California, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
Performance of Inherited Risk Assessment for Predicting Prostate Cancer From Prostate Biopsy
RECRUITING
-
Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer
RECRUITING · Phase 2
-
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
RECRUITING
-
Improving Health Literacy in African-American Prostate Cancer Patients
RECRUITING · NA
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.